STEVEN A. FLECKMAN APPOINTED TO BOARD OF APPLIED BIOSCIENCE INTERNATIONAL, INC.
ARLINGTON, Va., March 26 /PRNewswire/ -- Grover C. Wrenn, president and CEO of Applied Bioscience International (NASDAQ: APBI) announced today the appointment of Steven A. Fleckman to the board of directors of the Arlington-based company. Mr. Fleckman is a partner in the Austin, Texas law firm, Fleckman Johnson & Passman. From 1983 through 1992 he served as Chief Legal Counsel for Pharmaco (now Pharmaco LSR), an APBI subsidiary, and the world's largest provider of toxicology and clinical drug development services. Mr. Fleckman is credited with playing an instrumental role in guiding and developing Pharmaco to its present position as an international leader in its industry. Mr. Fleckman received his J.D. from Harvard Law School in 1975. He currently serves on the Texas State Bar Committee on Intellectual Property Law. Active in the Austin community, Mr. Fleckman was recently chosen to be a member in the 1993 Class of Leadership, Austin. APBI provides a broad range of inter-related services, including biological safety testing and clinical research and development through its Life Sciences Group, and assessment and management of chemical and environmental risk, agrochemical research and development, and related analytical chemistry services through its Environmental Sciences Group. These services are provided under contract to clients in the pharmaceutical, general chemical, agrochemical, and other industries worldwide. -0- 3/26/93 /CONTACT: John H. Timoney, senior vice president of Applied Bioscience International, 609-951-9090; or John J. McNamara of John McNamara Advertising, 212-509-7779, for Applied Bioscience International/ (APBI)
CO: Applied Bioscience International Inc. ST: Virginia IN: MTC SU: PER
SH -- NY035 -- 9503 03/26/93 14:34 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 26, 1993|
|Previous Article:||ENNIS BUSINESS FORMS, INC. DECLARES QUARTERLY DIVIDEND AND SETS RECORD DATE FOR ANNUAL STOCKHOLDERS' MEETING|
|Next Article:||KINARK ANNOUNCES APPOINTMENTS TO BOARD|